Market News AIOpen the app

B. Riley lowered its target price for Cue Biopharma to $25 from $83 but still thinks it's a good buy.

OpinionRead the original at marketscreener.com
Bad for CUE

B. Riley cut its share-price target from $83 to $25, signaling a much weaker view.

CUE · Cue Biopharma, Inc.

AI read · Bad for CUE

The AI's read

The change points to a much weaker view of what Cue's shares could be worth. Keeping its Buy rating is a real counterpoint, but it does not erase the large cut. The story gives no details about Cue's quarterly results, so they do not change this reading.

Get alerts for CUE

Follow Cue Biopharma, Inc. (CUE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CUE
Free on the App Store and Google Play, or on the web.